+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety, dosage, and preliminary antitumor effects of Pocenbrodib alone and combined with darolutamide in men with metastatic castration-resistant prostate cancer mCRPC who have progressed after prior therapies including potent anti-androgen treatments. This Phase 1b2a open-label study includes dose escalation and optimization to find the maximum tolerated dose and recommended Phase 2 doses of Pocenbrodib, both as monotherapy and in combination with darolutamide. The study has three arms in Phase 1b Pocenbrodib given once daily 5 days on2 days off, Pocenbrodib given twice daily continuously, and Pocenbrodib combined with darolutamide twice daily continuously as a safety run-in for combination therapy. Phase 2a further evaluates the combination in two cohorts receiving different recommended doses of Pocenbrodib plus darolutamide after progression following lutetium-Lu-177-vipivotide-tetraxetan PLUVICTO and before taxane chemotherapy. Safety is closely monitored throughout. Participants will undergo assessments including safety and tolerability checks, pharmacokinetic and pharmacodynamic measurements, and evaluations of antitumor activity over treatment cycles of 28 days, estimated up to six months. Laboratory tests, imaging, and prostate-specific antigen PSA measurements will be collected to assess responses. Monitoring for adverse events and dose optimization guides treatment throughout the study duration until disease progression or discontinuation.

Age: 18Years +MALEPhase 1Phase 2
19 locations
S

Actively Recruiting

Researchers are studying ASP5834 in adults with certain locally advanced, unresectable, or metastatic solid tumors that have specific KRAS gene mutations or amplifications. This study aims to understand how ASP5834 works in the body, find a suitable dose, and evaluate safety and tolerability when given alone or with panitumumab, a treatment for colorectal cancer. Participants include those with solid tumors who have not responded to or are ineligible for standard treatments. The study has two parts Dose Escalation and Dose Expansion. In Dose Escalation, small groups receive increasing doses of ASP5834 alone or with panitumumab only for colorectal cancer patients via intravenous infusion. The medical team reviews side effects to decide dosing for the next group. In Dose Expansion, groups receive the chosen ASP5834 doses alone or with panitumumab. Treatment cycles last 21 or 28 days, repeated until side effects, cancer progression, other treatments, or participant choice ends treatment. Participants will have clinic visits on set days during treatment, with extra visits early on to monitor safety and health. Scans will check cancer changes, and tumor samples may be taken during treatment or if cancer worsens. After treatment ends, participants have health checks every few months to monitor cancer status. The total study participation is expected to last about one year. Researchers measure safety, side effects, tumor response, survival, and drug behavior in the body.

Age: 18Years +All GendersPhase 1
22 locations
P

Actively Recruiting

Researchers are studying ziftomenib, an investigational oral drug, in combination with standard treatments for patients with acute myeloid leukemia AML who have specific genetic mutations such as NPM1 or KMT2A rearrangements. This Phase 1 trial aims to assess the safety, tolerability, and early signs of effectiveness of ziftomenib when added to existing AML therapies in both newly diagnosed and relapsedrefractory patients. The study includes several treatment groups where ziftomenib is combined with drugs like venetoclax, azacitidine, daunorubicin, cytarabine, and quizartinib. Patients receive these medications through oral, intravenous, or subcutaneous routes depending on the combination. Different arms focus on distinct patient groups based on genetic markers and prior treatment history. The study investigates dose levels and combinations including intensive chemotherapy regimens and targeted therapies over multiple treatment cycles. Participants will be monitored closely from the first day of treatment through up to 36 months, with regular assessments of side effects, blood tests, and response to therapy including remission rates. Researchers will track dose-limiting toxicities and adverse events, as well as disease outcomes like complete remission and measurable residual disease. Safety and effectiveness data will be collected through a series of treatment cycles, with follow-up continuing for up to three years to evaluate long-term impact and survival outcomes.

Age: 18Years +All GendersPhase 1
44 locations
E

Actively Recruiting

Researchers are evaluating the effects of therapeutic-dose heparin compared to usual care pharmacological thromboprophylaxis in patients hospitalized with community-acquired pneumonia CAP. The study focuses on the high incidence of hospitalizations due to CAP, which often leads to serious complications including thrombotic events that affect respiratory, cardiac, and other organs. This trial aims to explore whether therapeutic-dose heparin can improve outcomes by targeting inflammatory and thrombotic pathways, a strategy shown to help in COVID-19 but not yet studied in non-COVID-19 CAP. Participants are randomly assigned to one of two groups. One group receives therapeutic-dose low molecular-weight heparin LMWH or unfractionated heparin UFH daily for up to 14 days or until hospital discharge, whichever comes first. The other group receives the usual care thromboprophylaxis dose according to local practice, which is lower than the therapeutic dose. Treatments start as soon as possible after randomization. LMWH is preferred unless contraindicated, with dosing based on patient weight, while UFH may be used in cases of renal impairment. During the study, participants will be monitored for outcomes including survival at 30 days, bleeding events, thrombotic events, mechanical ventilation use, mortality at various timepoints, hospital-free days, and health-related quality of life. The study collects data up to 180 days after treatment. Safety monitoring includes tracking adverse events like bleeding and heparin-induced thrombocytopenia. Participation involves hospital stays expected to last at least 72 hours from randomization, with assessments throughout the treatment period and follow-up extending to 180 days.

Age: 18Years +All GendersPhase 3
68 locations
I

Actively Recruiting

Researchers are studying how receiving liver transplants from donors with HIV compares to receiving livers from donors without HIV in people who have HIV. The goal is to better understand the risks of opportunistic infections and cancer after transplant in these patients. This research builds on changes from the 2013 HIV Organ Policy Equity HOPE Act, which allowed people with HIV to receive organs from HIV-positive donors as part of research. Participants will receive liver transplants from either deceased donors with HIV or without HIV. The study monitors these groups over time to compare outcomes. The study tracks events from the time of transplant through at least 6 months, up to 4 years post-transplant, including infections, cancer, survival, graft function, and transplant complications. During the study, participants will be followed closely with assessments of infections, cancer, HIV control, graft survival, and adverse events. Researchers will measure the incidence of opportunistic infections or cancer and other health outcomes after transplant. The study lasts up to 4 years after transplant for each participant, with ongoing monitoring to gather comprehensive data on long-term health outcomes.

Age: 18Years +All GendersPhase Not Applicable
19 locations
N

Actively Recruiting

Researchers are working to improve care and outcomes for infants diagnosed with Hypoplastic Left Heart Syndrome HLHS. This observational study aims to expand a national registry to collect detailed clinical care, outcome, and developmental data on infants with HLHS from diagnosis through their first year of life. The study also focuses on promoting the use of agreed-upon care standards at pediatric cardiology centers and involving parents as active partners in improving treatment and results. The study uses a Collaborative Learning Network as its main approach, involving multiple pediatric cardiology centers to share information and improve care practices. Data collection includes monitoring how consensus care standards are implemented and their impact on care processes. The initiative gathers information during the infants first 12 months, particularly focusing on those undergoing the Norwood procedure. Participants will be infants diagnosed with HLHS or similar single-ventricle heart conditions, with data collected on their treatment, development, and outcomes. Researchers will assess the relationship between changes in care delivery and improvements in care processes over 15 months. Parents are engaged as partners throughout the study. The total follow-up period spans from diagnosis up to 12 months of age, with ongoing data gathering and quality improvement efforts.

Age: 0 - 15MonthsAll Genders
63 locations
E

Actively Recruiting

Healthy Volunteer

Pancreatic ductal adenocarcinoma PDAC is a severe form of cancer that is often detected too late for effective treatment. Current blood markers like serum carbohydrate antigen 19-9 CA19-9 are unreliable for early detection. Researchers developed a method analyzing exosomes containing microRNAs miRNAs to detect early-stage PDAC more accurately. This study aims to confirm this methods effectiveness in a larger international group. The study evaluates a diagnostic test called PANcreatic cancer Exosome Early detectiON PANXEON, which uses qRT-PCR to measure levels of 5 cell-free and 8 exosome miRNAs in blood plasma. Participants include individuals diagnosed with pancreatic ductal adenocarcinoma and those without the disease, divided into training and validation groups. The study is observational and collects plasma samples to assess these miRNA signatures. Participants will provide plasma samples before any curative treatment and undergo standard diagnostic and staging procedures. Researchers will monitor outcomes including the tests sensitivity, specificity, and accuracy over about one year. The study involves individuals with various stages of PDAC and controls without the disease, with ongoing data collection until the study completion date in 2030.

Age: 18Years +All Genders
13 locations
N

Actively Recruiting

Researchers are collecting information on people with pulmonary arterial hypertension PAH and chronic thromboembolic pulmonary hypertension CTEPH through the Pulmonary Hypertension Association Registry PHAR. This study aims to understand how these patients are evaluated, diagnosed, and treated at specialized Pulmonary Hypertension Care Centers across the U.S. It also looks at how well patients do over time and whether care follows recommended guidelines, with a goal to identify factors influencing patient outcomes. Participants include those with newly diagnosed or existing PAH or CTEPH, as well as pediatric patients with Group 3 pulmonary hypertension related to developmental lung disease, all within six months of their first outpatient visit to a PH Care Center. The registry collects detailed data including diagnosis, clinical status, socioeconomic factors, test results, treatments, and social history. Participants are followed over time to update changes in therapy, hospital visits, and survival. Throughout the study, participants provide ongoing information on their health status and treatments. Researchers collect data on diagnosis tests, therapy changes, hospitalizations, and survival rates over a 10-year period. The registry helps monitor adherence to guidelines and evaluates clinical predictors of disease progression. This long-term observation may improve care by highlighting effective treatment practices and patient outcomes.

Age: 0Years +All Genders
52 locations
E

Actively Recruiting

This clinical trial studies seladelpar, a drug being evaluated for its effects on people with primary biliary cholangitis PBC who have compensated cirrhosis. The main goal is to compare seladelpar with a placebo to see how it impacts event-free survival EFS, which measures the time until certain liver-related events occur over a period of up to 156 weeks. This research is led by Gilead Sciences and takes place in a phase 3 setting, aiming to better understand treatment outcomes for PBC patients with cirrhosis. Participants with Child-Pugh class A cirrhosis will receive 10 mg of seladelpar orally once daily, while those with Child-Pugh class B will receive 5 mg once daily, both for up to 36 months. Another group with either Child-Pugh class A or B will receive a placebo matching the study drug daily for the same duration. After 156 weeks, participants with Child-Pugh class A or B who remain on the study drug may continue seladelpar at the respective doses for an additional maximum of 3 years during an open-label extension phase. Participants will be monitored throughout the study with regular assessments to evaluate liver function and clinical events related to PBC and cirrhosis. Researchers will measure outcomes such as event-free survival, overall survival, time to hospitalization, and liver transplant-free survival. Safety and liver health will be closely followed using laboratory tests and imaging. The total participation time may extend up to several years, depending on continued study drug use and follow-up requirements.

Age: 18Years +All GendersPhase 3
218 locations
R

Actively Recruiting

Researchers are evaluating whether casdatifan combined with cabozantinib can improve progression-free survival compared to placebo plus cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma. The study focuses on patients who have previously received anti-PD-1 or anti-PD-L1 therapies in their most recent treatment, with no more than one prior metastatic treatment regimen. This is a randomized, double-blind, active-controlled phase 3 trial aimed at advancing treatment options for this patient group. Participants will be randomly assigned to receive either casdatifan and cabozantinib or placebo and cabozantinib, both taken orally. The study includes two treatment arms one experimental arm with casdatifan and cabozantinib, and a comparator arm with placebo and cabozantinib. Treatment is ongoing, with monitoring for up to approximately 33 months for key outcomes, and follow-up for overall survival up to about 64 months. Throughout the study, participants will undergo regular assessments including imaging scans evaluated by a blinded independent review to measure tumor response and progression. Researchers will track progression-free survival, overall survival, response rates, duration of response, disease control, and treatment-related adverse events. Symptom changes will also be monitored using patient-reported measures. The total participation duration may extend up to several years to capture long-term outcomes and safety data.

Age: 18Years +All GendersPhase 3
191 locations